700 patients110,866 observations180 daysLIVE

Patient P-02460

Synthetic patientMETA-24 · Day 110 · 55–64 · F · baseline S18Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Favorable
GI state
Stable
Inflammatory state
Improving
Nutritional resilience
Stable
Discontinuation risk
50%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 startedBaseline state S18
  2. Day 72 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 74 GI-04 recommendedGI Support Protocol GI-04
  4. Day 75 Patient acceptedStarted GI-04 in the companion
  5. Day 83 GI symptom burden −33% vs expectedGI Support Protocol GI-04
  6. Day 89 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 72.

Primary contributors, last 14 days
  • Treatment adherence-28
  • Inflammatory activity-7
  • Nutritional resilience+4
  • GI instability-3
  • Toxicity-3

What helped?

  • GI Support Protocol GI-04Day 74
    Result: symptom burden −33%
LIFE OS recommendation
Dietary Support Protocol NP-02
53%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 73% showed improvement
  • median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes
Wearable
54 min
improving · +4.9 vs previous 14 d
Sleep duration
Wearable
8 h
stable · +0.0 vs previous 14 d
Energy level
Daily log
4.2/10
worsening · -0.6 vs previous 14 d
Steps
Wearable
6,269
improving · +437 vs previous 14 d
GI burden
Companion
52.3/100
stable · +0.9 vs previous 14 d
Adherence
Companion
58.9 %
worsening · -16.8 vs previous 14 d
Sleep quality
Wearable
56.1/100
stable · -1.0 vs previous 14 d
Glucose, CGM daily mean
CGM
134 mg/dL
stable · -3.0 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 44 from the failing basin, 46 from restoration.

Would help
  • NP-02 Dietary Support Protocol
    62% improved among 29 similar · onset 10 d · confidence 56%
  • DT-01 Dosing / Timing Recommendation
    80% improved among 5 similar · onset 5 d · confidence 56%
  • More protein
    GI -3.2 next day on high-intake days · n 18
Would not help
  • Keep histamine low
    GI +3.2 next day on high-intake days · n 21
  • Keep fat low
    GI +2.7 next day on high-intake days · n 23
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Histamine load
    +3.2detractor · 95%
  • Protein
    -3.2supporter · 95%
  • Dietary fat load
    +2.7detractor · 95%
  • Caffeine
    +1.3no signal · 39%
  • Simple carbohydrates
    +1no signal · 24%
  • Insoluble fibre
    -0.5no signal · 15%
  • Ultra-processed food
    -0.3no signal · 15%
  • Alcohol
    -0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 52 and rising
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 28/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 45
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 47
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Normal metabolizer
    Expected exposure
  • GLP1R rs6923761 A
    Altered receptor sensitivity
Microbiome
Shannon diversity 3.1 · butyrate capacity 28/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
56 ms
Sleep
7.2 h
Steps
5,828
Resting HR
65 bpm
Daily log: GI score 52, nutritional resilience 47, adherence 59.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the dose at the same time relative to your evening meal
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0206047%S14GI-04improved54
P-0229943%S14GI-04improved59
P-0267437%S02NP-02improved48
P-0216534%S14ME-01improved59
P-0217633%S14GI-04improved52
P-0239833%S06GI-04improved63
P-0250833%S14ME-01improved51
P-0221632%S11GI-04improved53
P-0229832%S14GI-04improved65
P-0241032%S01GI-04improved55
P-0257532%S14ME-01improved73
P-0266632%S14ME-01improved51